Organizations like yours are familiar to us. We are chemists, engineers, molecular biologists, researchers, and scientists who combine our technical understanding with legal, regulatory, and compliance excellence to provide you with well-informed counsel – from your patent portfolio development, protection, and monetization strategies to market entry and exit strategies.
Whether you are an inventor, start-up, venture capitalist, investor, Fortune 50 or Fortune 500 company, or research institution we help people like you on all aspects of pharmaceuticals, biotechnology and medical devices. We understand that regulatory and compliance will dominate your thinking – and can help you meet your requirements on every issue from M&A to tax, HR and real estate.
We know that often in this industry, time is of the essence, and we are proud that we continually demonstrate that we can work at speed without compromising on efficiency. This is demonstrated by our looking at patents for potential vaccines and detection methods, as well as dealing with urgent approval for medical devices and personal protective equipment.
Whatever your background, we can help you commercialize your inventions, protect key intellectual property and structure your business and partnerships to best enable you to bring the next generation of medicines, products and services to market.
Our lawyers use their experience and knowledge of the life sciences and healthcare fields to work across many cases and sectors. Some of our recent work includes:
- a pan-European review of new product launch marketing materials for EU and country-by-country compliance
- prosecution of pharmaceutical and biotechnology patent applications through our large U.S. patent team. We also have patent attorney capability in Finland and South Africa
- patent litigation across the U.S. and Europe including Hatch-Waxman launch strategies
- assessment of mobile apps as medical devices and advice on classification
- antitrust litigation in relation to pricing and market access and to parallel importation, including refusal to supply issues
- regulatory litigation concerning data exclusivity
- advice on clinical trials agreements and regulation
- implementing an EU-wide privacy compliance program and preparing for the arrival of the new data privacy law
Latest Публикации
- legal updatesThe EDPB’s new scientific research guidelines: a welcome route map, but no shortcut for “research” by assertion
- legal updatesHong Kong: Open consultation on listing reforms
- legal updatesEU Legislation Roundup: February 2026
- legal updatesManaging M&A uncertainty in the EU’s evolving regulatory landscape
Latest News
- новини от насEversheds Sutherland Advises The Centurion Foundation on Completed Acquisition of Roger Williams Medical Center and Fatima Hospital
- новини от клиентиEversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
- новини от клиентиEversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
- новини от клиентиWe advised Icare Finland in a share transaction
legal updates
28 април 2026 г.
The EDPB’s new scientific research guidelines: a welcome route map, but no ...
legal updates
14 април 2026 г.
Hong Kong: Open consultation on listing reforms
legal updates
05 март 2026 г.
EU Legislation Roundup: February 2026
legal updates
12 февруари 2026 г.
Managing M&A uncertainty in the EU’s evolving regulatory landscape
новини от нас
20 март 2026 г.
Eversheds Sutherland Advises The Centurion Foundation on Completed Acquisit...
новини от клиенти
06 ноември 2025 г.
Eversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
новини от клиенти
06 септември 2024 г.
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of C...
новини от клиенти
04 септември 2024 г.
We advised Icare Finland in a share transaction